Neuro Protective

Neurotech expands exclusive license to include all neurological disorders

Finfeed Archived Mar 02, 2021

Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.

Neurotech’s key near-term objectives

Finfeed Archived Jan 21, 2021

Neurotech International Limited (ASX: NTI) has provided a comprehensive overview and update regarding the company’s cannabis strains, development strategy and some of the key near-term objectives expected to be delivered.